Search

  • HOME
  • Search
Review Article
Recent advances in the diagnosis and management of childhood acute promyelocytic leukemia
Eun Sun Yoo
Clin Exp Pediatr. 2011;54(3):95-105.   Published online March 31, 2011

Since the successful introduction of all-trans-retinoic acid (ATRA) and its combination with anthracycline-containing chemotherapy, the prognosis for acute promyelocytic leukemia (APL) has markedly improved. With ATRA and anthracycline-based-chemotherapy, the complete remission rate is greater than 90%, and the long-term survival rate is 70-89%. Moreover, arsenic trioxide (ATO), which was introduced for APL treatment in 1994, resulted in excellent remission rates...

Original Article
Synergistic Cytotoxicity of Arsenic Trioxide and Sulindac Against Neuroblastoma
Du Young Choi
Clin Exp Pediatr. 2004;47(9):1002-1007.   Published online September 15, 2004
Purpose : Recent clinical studies have shown that arsenic trioxide(As2O3) at low concentrations induces complete remission without significant toxicity in patients with refractory acute promyelocytic leukemia(APL). Like APL cells, neuroblastoma(NB) cells are thought to be arrested at an early stage of differentiation, and can respond with retinoic acid treatment. Sulindac, a nonsteroidal antiinflammatory drug, was reported to induce antitumor activity...
Case Report
A Case of Relapsed Acute Promyleocytic Leukemia Induced Remission with Arsenic Trioxide(As2O3)
Jin Hye Park, Heung Sik Kim, Chin Moo Kang
Clin Exp Pediatr. 2000;43(8):1132-1136.   Published online August 15, 2000
Acute promyelocytic leukemia(APL) is a unique entity in the spectrum of acute myelogenous leukemia. It has several characteristic features, including distinctive morphology, chromosomal translocation, t(15:17), disseminated intravascular coagulation and effect on retinoic acid. Retinoic acid which is a derivative of vitamin A induces differentation of APL cells in vitro and in vivo, but its cessation induces relapse of APL. Arsenic...
Original Article
Anticancer Effect of Arsenic Trioxide in Acute Promyelocytic Leukemia
Ki Young Song, Jin Hye Park, Yoon Jung Cho, Won Ki Baek, Ki Young Kwon, Heung Sik Kim, Chin Moo Kang
Clin Exp Pediatr. 2000;43(3):327-334.   Published online March 15, 2000
Purpose : Acute promyelocytic leukemia(APL or AML, M3) represents an unique model for cancer research in terms of biological and clinical features. Since 1988, it has been widely confirmed that all-trans retinoic acid(ATRA) can induce complete clinical remission in over 85% of APL patients by a differentiation process, with PML-RARα protein possibly being the direct target of ATRA. However, ATRA...
  • PubMed Central
  • PubMed
  • Scopus
  • Directory of Open Access Journals (DOAJ)